Fluicell initiates collaboration with Cellectricon to validate tissue-based models

Today, we had the pleasure to announce that we have initiated a collaboration with the internationally recognized CRO company Cellectricon to validate our tissue-based research models using Cellectricon’s infrastructure of standard technologies used in drug development.

Fluicell’s CEO Carolina Trkulja comments:

"Cellectricon are internationally recognized experts in in vitro research technology, not least in the field of neurodegenerative diseases, and we are very pleased to be able to initiate this collaboration with them. Through the collaboration, we gain access to a large number of workflows of central importance in drug development., which entails a significant capacity enhancement for the validation of our models. With the validation of our tissue models that the collaboration enables, we will be able to significantly strengthen our capacity to reach out to new customers and partners in the pharmaceutical industry, which is central to Fluicell's commercial expansion."

The collaboration between Fluicell and Cellectricon will focus on validating Fluicell's bioprinted tissues for use together with a variety of research techniques with broad application in early-stage drug development. Among the technologies that Fluicell will be able to use are for example microarray technology, an important technique for cardiac tissue and neuronal screening, whose compatibility with Nexocyte tissues we have previously determined. Through the agreement, we will also gain access to high-content imaging platforms, functional genomics technology and large-scale protein analysis techniques.

Link to the full press release (in Swedish).

About Cellectricon

Cellectricon is a leading provider of neurobiology in vitro research services. The company’s mission is to create groundbreaking in vitro concepts that will advance the neuroscience research field and enable clients from the pharmaceutical industry to conduct successful drug discovery programs. The experienced team of neurobiologists combines drug discovery expertise and disease area knowledge with cutting-edge technologies to create complex disease models and assays for functional and morphological screening. Cellectricon’s services are focused on the accelerating target and lead discovery programs in the areas of Peripheral Neuropathies, Neuroinflammation, Neurodegeneration and Neuroplasticity.

Image courtecy of Cellectricon AB

Share this article: